<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04979988</url>
  </required_header>
  <id_info>
    <org_study_id>B7461038</org_study_id>
    <nct_id>NCT04979988</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients</brief_title>
  <official_title>Retrospective, Multicenter, Observational Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the clinical real world outcomes of lorlatinib in second/later line setting&#xD;
      anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) to TKI sequence sequence&#xD;
      treatment after failure of alectinib as a first-line treatment in Japanese ALK positive&#xD;
      non-small cell lung cancer (NSCLC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a post-approval, company-sponsored, observational study. This study is a&#xD;
      multicenter, non-interventional, retrospective, chart review of patients with ALK+ NSCLC&#xD;
      patients treated using lorlatinib as the second/later line therapy in Japan after failure of&#xD;
      alectinib treatment as the first line therapy from 20 November 2018.&#xD;
&#xD;
      All decisions regarding clinical management and treatment of the participating patients were&#xD;
      made by an investigator as part of standard care in real-world clinical setting and were not&#xD;
      contingent upon the patient's participation in the study. Data will be collected if available&#xD;
      per study site. Patients in this study are those who started treatment with lorlatinib from 1&#xD;
      May 2019 to 31 December, 2020 in clinical practice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Description of patient characteristics at baseline (at the timing of alectinib initiation date) and at lorlatinib initiation date</measure>
    <time_frame>1 May 2019 to 15 OCT 2021</time_frame>
    <description>Age&#xD;
Sex&#xD;
Body mass index (BMI)&#xD;
Eastern Cooperative Oncology Group Performance Status (ECOG PS)&#xD;
NSCLC histopathological subtype&#xD;
Number and site of metastases&#xD;
Complications/medical history (related to history of treatment for ALK+ NSCLC)&#xD;
Smoking history&#xD;
ALK test result (ALK testing method, date of test result/diagnosis and test result)&#xD;
# of treatment regimens administered to the target disease prior to the start of lorlatinib treatment&#xD;
Time-to-treatment failure (TTF) for lorlatinib as the second line and the 3rd/later line</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>- Reason for discontinuation of each treatment line therapy</measure>
    <time_frame>1 May 2019 to 15 OCT 2021</time_frame>
    <description>The reasons for discontinuation of each treatment will be categorized as disease progression, adverse events, and others.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Objective response of lorlatinib as the second line and the 3rd/later line</measure>
    <time_frame>1 May 2019 to 15 OCT 2021</time_frame>
    <description>Evaluate Objective Response of lorlatinib as 2nd/3rd or later line in Real World</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- TTF of alectinib and subsequent therapy except for lorlatinib</measure>
    <time_frame>1 May 2019 to 15 OCT 2021</time_frame>
    <description>Evaluate TTF of alectinib in Real World</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Objective response of alectinib</measure>
    <time_frame>1 May 2019 to 15 OCT 2021</time_frame>
    <description>Evaluate Objective Response of alectinib in Real World</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Combined TTF</measure>
    <time_frame>1 May 2019 to 15 OCT 2021</time_frame>
    <description>combined TTF will be defined as the sum of alectinib and subsequent therapy including TTF of lorlatinib</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>ALK-positive Non-small-cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Japanese patients with ALK+ NSCLC who received lorlatinib</arm_group_label>
    <description>lorlatinib as the second-line or later therapy after failure of alectinib treatment as the firstline therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lortlatinib</intervention_name>
    <description>as provided in real world practice</description>
    <arm_group_label>Japanese patients with ALK+ NSCLC who received lorlatinib</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with ALK-positive lung cancer diagnosed and confirmed in the medical record as&#xD;
        receiving alectinib in the 1st line and lorlatinib in the 2nd line or later between May&#xD;
        2019 and December 2020.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed NSCLC, with any tumor, node and metastasis&#xD;
             (TNM) stage.&#xD;
&#xD;
          -  Confirmed ALK gene rearrangement by any validated test.&#xD;
&#xD;
          -  Confirmed the treatment with alectinib in the first line setting as systemic therapy&#xD;
             in the medical record.&#xD;
&#xD;
          -  Confirmed the start treatment with lorlatinib as the second/later-line therapy from&#xD;
             1st May 2019 to 31st December 2020.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -Participating on any clinical trials of which final results has not yet been reported&#xD;
        during the study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fujita Health University Hospital</name>
      <address>
        <city>Toyoake-City</city>
        <state>Aichi</state>
        <zip>470-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cancer Center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>241-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kurashiki Central Hospital</name>
      <address>
        <city>Kurashiki</city>
        <state>Okayama</state>
        <zip>710-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kinki-Chuo Chest Medical Center</name>
      <address>
        <city>Sakai-shi</city>
        <state>Osaka-fu</state>
        <zip>591-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kansai Medical University Hirakata Hospital</name>
      <address>
        <city>Hirakata-city</city>
        <state>Osaka</state>
        <zip>573-1191</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka International Cancer Institute</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <zip>541-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kinki University Hospital</name>
      <address>
        <city>Osakasayama</city>
        <state>Osaka</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center</name>
      <address>
        <city>Sunto-gun</city>
        <state>Shizuoka</state>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jichi Medical University Hospital</name>
      <address>
        <city>Shimotsuke</city>
        <state>Tochigi</state>
        <zip>329 0498</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Juntendo University Hospital</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Iwakuni Clinical Center</name>
      <address>
        <city>Iwakuni City</city>
        <state>Yamaguchi</state>
        <zip>740-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization, Yamaguchi-Ube Medical Center</name>
      <address>
        <city>Ube</city>
        <state>Yamaguchi</state>
        <zip>755-0241</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital of JFCR</name>
      <address>
        <city>Koto-ku, Tokyo</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toyama Prefectural Central Hospital</name>
      <address>
        <city>Toyama</city>
        <zip>930-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B7461038</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>July 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALK</keyword>
  <keyword>Lorlatinib</keyword>
  <keyword>Alectinib</keyword>
  <keyword>Real World</keyword>
  <keyword>retrospective</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

